The impact of hepatitis C virus infection on methadone maintenance treatment

Mount Sinai Journal of Medicine

Volumn 67, Issue 5-6, 2000, Pages 437-443

  Novick, David M ^a,b,c,d  

^a KETTERING MEDICAL CENTER   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d Digestive Specialists Inc   (United States)

Author keywords

Alcoholism; Epidemiology; Hepatitis C; Heroin; Injection drug use; Methadone

Indexed keywords

ALCOHOL; ALPHA2B INTERFERON; DIAMORPHINE; HEPATITIS C ANTIBODY; METHADONE; OPIATE; RIBAVIRIN;

ALCOHOLISM; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE SEVERITY; HEPATITIS C; HEPATITIS C VIRUS; HEROIN DEPENDENCE; HUMAN; INTRAVENOUS DRUG ABUSE; METHADONE TREATMENT; MORBIDITY; OPIATE ADDICTION; REMISSION; SEROPREVALENCE; UNITED STATES;

ALCOHOLISM; ANALGESICS, OPIOID; ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; METHADONE; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 0033744947     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (71)

1. Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. In: O'Brien CP, Jaffe JH, editors. Addictive states. New York: Raven Press; 1992. pp. 205-230.
2. Novick DM, Haverkos HW, Teller DW. The medically ill substance abuser. In: Lowinson JM, Ruiz P, Millman RB, Langrod JG, editors. Substance abuse: A comprehensive textbook, 3rd ed. Baltimore: Williams and Wilkins; 1997. pp. 534-550.
3. Choo Q-L, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362.
4. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
5. Purcell R. The hepatitis C virus: Overview. Hepatology 1997; 26(Suppl 1):11S-14S.
6. Simmonds P, Holmes EC, Cha T-A, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74:2391-2399.
7. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93:15394-15399.
8. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(Suppl 1):62S-65S.
9. Galmiche JP. French consensus conference on hepatitis C: Screening and treatment. Gut 1998; 42:892-898.
10. Belle SH, Beringer KC, Detre KM. Recent findings concerning liver transplantation in the United States. In: Cecka JM, Terasaki PI, editors. Clinical transplants 1996. 1st ed. Los Angeles: UCLA Tissue Typing Laboratory; 1997. pp. 15-29.
11. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: Lessons from the Vancouver injecting drug use study. AIDS 1997; 11:F59-F65.
12. Kemp R, Miller J, Lungley S, Baker M. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations. N Z Med J 1998; 111:50-53.
13. Woodfield DG, Harness M, Rix-Trott K. Hepatitis C virus infections in oral and injectable drug users. N Z Med J 1993; 106:332-334.
14. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74:212-220.
15. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: The prevalence of the hepatitis C. hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655-661.
16. Novick DM, Reagan KJ, Croxson TS, et al. Hepatitis C virus serology in parenteral drug users with chronic liver disease. Addiction 1997; 92:167-171.
17. Moaven LD, Crofts N, Locarnini SA. Hepatitis C virus infection in Victorian injecting drug users in 1971 [letter]. Med J Aust 1993; 158:574.
18. Lau JYN, Davis GL, Prescott LE, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med 1996; 124:868-876.
19. McCashland TM, Schafer DF. Hepatitis C: Sexually exposed? Am J Gastroenterol 1996; 91:2069-2070.
20. Gabrielli C, Zannini A, Corradini R, Gafa S. Spread of hepatitis C virus among sexual partners of HCVAb positive intravenous drug users. J Infect 1994; 29:17-22.
21. Soto B, Rodrigo L, Garcia-Bengoechea M, et al. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings. J Intern Med 1994; 236:515-519.
22. Villano SA, Vlahov D, Nelson KE, et al. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35:3274-3277.
23. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust 1997; 167:17-20.
24. Crofts N, Jolley D, Kaldor J, et al. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health 1997; 51:692-697.
25. Chetwynd J, Brunton C, Blank M, et al. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme. N Z Med J 1995; 108:364-366.
26. Chamot E, Hirschel B, Deglon JJ, Perrin LH. Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme. AIDS 1992; 6:430-431.
27. Selvey LA, Denton M, Plant AJ. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: Factors influencing hepatitis C serostatus. Aust N Z J Public Health 1997; 21:102-104.
28. Crofts N, Nigro L, Oman K, et al. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997; 92:999-1005.
29. Novick DM, Joseph H, Croxson TS, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med 1990; 150:97-99.
30. Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA 1988; 260:3025-3029.
31. Bell J, Chan J, Kuk A. Investigating the influence of treatment philosophy on outcome of methadone maintenance. Addiction 1995; 90:823-830.
32. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate-vs high-dose methadone in the treatment of opioid dependence: A randomized trial. JAMA 1999; 281:1000-1005.
33. Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology 1997; 26(Suppl 1):15S-20S.
34. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325:98-104.
35. Inglesby TV, Rai R, Astemborski J, et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999; 29:590-596.
36. Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995; 90:1250-1257.
37. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs. intravenous drug use. Hepatology 1993; 18:1338-1343.
38. Kreek MJ, Gutjahr CL, Garfield JW, et al. Drug interactions with methadone. Ann N Y Acad Sci 1976; 281:350-371.
39. Kreek MJ, Oratz M, Rothschild MA. Hepatic extraction of long- and short-acting narcotics in the isolated perfused rabbit liver. Gastroenterology 1978; 75:88-94.
40. Novick DM, Kreek MJ, Fanizza AM, et al. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 1981; 30:353-362.
41. Novick DM, Kreek MJ, Arns PA, et al. Effect of severe alcoholic-liver disease on the disposition of methadone in maintenance patients. Alcohol Clin Exp Res (NY) 1985; 9:349-354.
42. Lok ASF, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology 1997; 26(Suppl 1):48S-56S.
43. Schiff ER. Hepatitis C and alcohol. Hepatology 1997; 26(Suppl 1):39S-42S.
44. McFarlane IG. Hepatitis C and alcoholic liver disease. Am J Gastroenterol 1993; 88:982-988.
45. Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis 1995; 15:101-109.
46. Mendenhall CL, Moritz T, Rouster S, et al. Epidemiology of hepatitis C among veterans with alcoholic liver disease. Am J Gastroenterol 1993; 88:1022-1026.
47. Verbaan H, Andersson K, Eriksson S. Intravenous drug abuse -the major route of hepatitis C virus transmission among alcohol-dependent individuals? Scand J Gastroenterol 1993; 28:714-718.
48. Fong TL, Kanel GC, Conrad A, et al. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease. Hepatology 1994; 19:554-557.
49. Brillanti S, Masci C, Siringo S, et al. Serological and histological aspects of hepatitis C virus infection in alcoholic patients. J Hepatol 1991; 13:347-350.
50. Rosman AS, Waraich A, Galvin K, et al. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol 1996; 91:498-505.
51. Novick DM, Enlow RW, Gelb AM, et al. Hepatic cirrhosis in young adults: Association with adolescent onset of alcohol and parenteral heroin abuse. Gut 1985; 26:8-13.
52. Novick DM, Stenger RJ, Gelb AM, et al. Chronic liver disease in abusers of alcohol and parenteral drugs: A report of 204 consecutive biopsy-proven cases. Alcohol Clin Exp Res (NY) 1986; 10:500-505.
53. Caldwell SH, Li X, Rourk RM, et al. Hepatitis C infection by polymerase chain reaction in alcoholics: False-positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol 1993; 88:1016-1021.
54. Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 20;1115-1120.
55. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27:1717-1722.
56. Ostapowicz G, Watson KJR, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27:1730-1735.
57. Mendenhall CL, Seeff L, Diehl AM, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: Their prevalence and clinical relevance. Hepatology 1991; 14:581-589.
58. Wiley T, McCarthy M, Breidi B, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28:805-809.
59. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
60. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-1432.
61. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127:875-881.
62. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon in chronic hepatitis C: A quantitative evaluation of histology by meta-analysis. J Hepatol 1997; 26:1187-1199.
63. Jouet P, Roudot-Thoraval F, Dhumeaux D, et al. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994; 106:686-690.
64. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286-290.
65. Novick DM, Richman BL, Friedman JM, et al. The medical status of methadone maintenance patients in treatment for 11-18 years. Drug Alcohol Depend 1993; 33:235-245.
66. Novick DM, Ochshorn M, Ghali V, et al. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J Pharmacol Exp Ther 1989; 250:606-610.
67. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998; 280:1936-1943.
68. Wren CS. Doctors praise new methadone effort: U.S. to widen availability of drug to treat heroin addiction. New York Times 1998 Sep 30; Sect. B:3.
69. Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280:544-546.
70. Levine RA. Treating historically mild chronic hepatitis C: Monotherapy, combination therapy, or tincture of time? Ann Intern Med 1998; 129:323-326.
71. Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998; 26:257-260.